Real-Time Quaking-Induced Conversion (RT-QuIC)
Introduction
Alpha Synuclein Rt Quic Assay is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Real-Time Quaking-Induced Conversion (RT-QuIC) is an ultrasensitive biochemical assay that detects misfolded protein aggregates in cerebrospinal fluid (CSF) and other biological tissues. Originally developed for prion diseases, RT-QuIC has been adapted to detect α-synuclein aggregates in [Parkinson's disease](/diseases/parkinsons-disease), Dementia with Lewy Bodies, and Multiple System Atrophy, providing a powerful diagnostic tool for synucleinopathies[@fairfoul2016].
Overview
...Real-Time Quaking-Induced Conversion (RT-QuIC)
Introduction
Alpha Synuclein Rt Quic Assay is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Real-Time Quaking-Induced Conversion (RT-QuIC) is an ultrasensitive biochemical assay that detects misfolded protein aggregates in cerebrospinal fluid (CSF) and other biological tissues. Originally developed for prion diseases, RT-QuIC has been adapted to detect α-synuclein aggregates in [Parkinson's disease](/diseases/parkinsons-disease), Dementia with Lewy Bodies, and Multiple System Atrophy, providing a powerful diagnostic tool for synucleinopathies[@fairfoul2016].
Overview
Mermaid diagram (expand to render)
[Alpha-Synuclein](/proteins/alpha-synuclein) RT-QuIC (Real-Time Quaking-Induced Conversion) is an ultrasensitive diagnostic assay that detects misfolded [alpha-synuclein](/proteins/alpha-synuclein) aggregates in cerebrospinal fluid (CSF) and other biological samples. It exploits the ability of pathological alpha-synuclein to template the conversion of recombinant alpha-synuclein into amyloid fibrils.
This assay enables early and accurate diagnosis of Parkinson's Disease, Dementia with Lewy Bodies, and Multiple System Atrophy by detecting prion-like alpha-synuclein seeds up to a decade before clinical symptoms appear.
Principle of RT-QuIC
RT-QuIC exploits the seed-dependent aggregation properties of misfolded proteins. The assay works as follows:
Reaction Mechanism
Substrate: Recombinant full-length or truncated α-synuclein protein is used as substrate
Seeding: Patient CSF contains pathological α-synuclein seeds (oligomers or fibrils)
Amplification: In the presence of seeds, normal α-synuclein monomers misfold and aggregate
Detection: Thioflavin T (ThT) fluorescence is monitored in real-timeReaction Conditions
- Temperature: 30-42°C (typically 37°C)
- Shaking: Intermittent or continuous quaking
- Duration: 40-100 hours
- Substrate: Full-length α-synuclein (1-140 aa) or truncated versions
- Buffers: Phosphate saline with salts and crowding agents
Clinical Applications
Parkinson's Disease Diagnosis
RT-QuIC detects α-synuclein seeds in CSF with high sensitivity (85-95%) and specificity (95-100%) for Parkinson's disease[@rossi2020]. This represents a major advance because:
- Pre-motor stage detection: Can identify PD before motor symptoms
- Differential diagnosis: Helps distinguish PD from other movement disorders
- Prodromal identification: Detects individuals with REM sleep behavior disorder who will develop PD
Dementia with Lewy Bodies
RT-QuIC shows high sensitivity (95-100%) for DLB, making it useful for differentiating from other dementias[@bongianni2017]:
| Condition | Sensitivity | Specificity |
|-----------|-------------|-------------|
| Parkinson's Disease | 85-95% | 95-100% |
| Dementia with Lewy Bodies | 95-100% | 90-98% |
| Multiple System Atrophy | 80-90% | 95-100% |
| Progressive Supranuclear Palsy | 10-20% | 95-100% |
| [Alzheimer's Disease](/diseases/alzheimers-disease) | 0-5% | 99-100% |
Multiple System Atrophy
RT-QuIC can detect α-synuclein aggregates characteristic of MSA (predominantly neuronal, not glial)[@singer2020]. The assay shows:
- Sensitivity: 80-90%
- Specificity: 95-100% vs. other neurodegenerative diseases
Sample Collection and Processing
CSF Collection
Lumbar Puncture: Performed at L3-L4 or L4-L5
Volume: 10-20 mL recommended
Storage: Centrifuge within 2 hours, store at -80°C
Freeze-thaw: Minimize cycles (max 3)Pre-analytical Factors
| Factor | Effect | Recommendation |
|--------|--------|----------------|
| Blood contamination | False positives | Avoid RBC contamination |
| Storage time | Decreased sensitivity | Test within 6 months |
| Repeated freeze-thaw | Reduced signal | Limit to 3 cycles |
| Sample age | Variable | Fresh testing preferred |
Sensitivity and Specificity
RT-QuIC demonstrates excellent diagnostic performance in large validation studies:
Parkinson's Disease:
- Sensitivity: 87.7% (95% CI: 82.0-92.2%)
- Specificity: 96.7% (95% CI: 92.0-99.0%)
Dementia with Lewy Bodies:
- Sensitivity: 96.2% (95% CI: 89.2-99.2%)
- Specificity: 93.8% (95% CI: 87.8-97.6%)
Reproducibility
- Inter-laboratory agreement: > 90%
- Intra-class correlation coefficient: 0.85-0.92
- Coefficient of variation: 15-25%
Advantages Over Other Methods
vs. Alpha-Synuclein ELISA
| Feature | RT-QuIC | ELISA |
|---------|---------|-------|
| Detects | Seed-competent aggregates | Total α-synuclein |
| Sensitivity | Much higher | Moderate |
| Specificity | Higher | Lower |
| Turnaround | 2-5 days | 1-2 days |
vs. Skin Biopsy
| Feature | RT-QuIC | Skin Biopsy |
|---------|---------|-------------|
| Invasiveness | Minimal (LP) | Moderate (biopsy) |
| Sensitivity | 85-100% | 75-90% |
| Standardization | Good | Variable |
| Cost | Lower | Higher |
Limitations and Challenges
Technical Limitations
Turnaround time: 2-5 days for complete analysis
Equipment requirements: Fluorescence plate reader needed
Standardization: Inter-lab variability still exists
False negatives: Some true cases test negativeClinical Limitations
Pre-analytical variability: Sample handling affects results
Disease stage sensitivity: Lower sensitivity in early disease
Not disease-specific: Cannot distinguish all synucleinopathies
Limited availability: Not yet routine in all clinical labsResearch Applications
Biomarker Development
RT-QuIC enables:
- Disease progression monitoring: Seed levels may correlate with progression
- Treatment response: Could serve as pharmacodynamic marker
- At-risk identification: Testing prodromal populations
Therapeutic Trials
RT-QuIC is being incorporated into clinical trials as:
- Diagnostic enrichment: Ensure correct diagnosis
- Target engagement: Monitor α-synuclein seed reduction
- Progression marker: Track disease modification
Future Directions
Blood-Based RT-QuIC
Emerging methods aim to detect α-synuclein seeds in blood samples, which would enable:
- Wider screening programs
- Easier longitudinal monitoring
- Reduced invasiveness
Multi-protein Panels
Combining α-synuclein RT-QuIC with other biomarkers:
- α-synuclein + [tau](/proteins/tau) (differential diagnosis)
- α-synuclein + [β-amyloid](/proteins/amyloid-beta) (AD differentiation)
- α-synuclein + [NfL](/proteins/nfl-protein)) (disease progression)
External Links
- [PubMed - RT-QuIC Alpha-Synuclein](https://pubmed.ncbi.nlm.nih.gov/?term=alpha-synuclein+RT-QuIC)
- [Nature - Seed Amplification Assay](https://www.nature.com/articles/s41582-019-0180-6)
- [NIH - Prion-Like Aggregation](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590342/)
- [Michael J Fox Foundation - Diagnostic](https://www.markermichaeljfox.org/)
- [Parkinson's Foundation - Early Detection](https://www.parkinson.org/Living-with-Parkinsons/Treatment/Care-Team)
Background
The study of Alpha Synuclein Rt Quic Assay has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
Fairfoul G, et al, (2016) (2016)
Rossi M, et al, (2020) (2020)
Bongianni M, et al, (2017) (2017)
Singer W, et al, (2020) (2020)
Iranzo A, et al, (2016) (2016)